Nanox to Report Second Quarter 2023 Financial Results on August 17, 2023
August 02 2023 - 4:05PM
NANO-X IMAGING LTD ("
Nanox" or the
"
Company," Nasdaq: NNOX) will report its financial
results for the second quarter ended June 30, 2023 before
market open on Thursday, August 17, 2023. Erez Meltzer, Chief
Executive Officer, and Ran Daniel, Chief Financial Officer,
will host a conference call to review these results and provide a
business update on the same day at 8:30 a.m. ET.
Interested parties may register for the conference call using
the following link: Nanox Q2 2023 Earnings Registration Link. You
may access the live webcast of the conference call by using the
following link: Nanox Q2 2023 Earnings. Both links will be posted
in the Investor Relations section of the Nanox website
at Events and Presentations.
About Nanox
We, NANO-X IMAGING LTD or Nanox (Nasdaq: NNOX), are focused on
applying our proprietary medical imaging technology and solutions
to make diagnostic medicine more accessible and affordable across
the globe.
Nanox’s vision is to increase access, reduce costs and enhance
the efficiency of routine medical imaging technology and processes,
in order to improve early detection and treatment, which Nanox
believes is key to helping people achieve better health outcomes,
and, ultimately, to save lives.
The Nanox ecosystem includes: the FDA-cleared Nanox.ARC – a
multi-source Digital Tomosynthesis system that is cost-effective,
and user-friendly; an AI-based suite of algorithms that augment the
readings of routine CT imaging to highlight early signs often
related to chronic disease, (Nanox.AI); a cloud-based
infrastructure (Nanox.CLOUD); and a proprietary decentralized
marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that
provides remote access to radiology and cardiology experts; and a
comprehensive teleradiology services platform
(Nanox.MARKETPLACE).
Together, Nanox’s products and services create a worldwide,
innovative, and comprehensive solution that connects medical
imaging solutions, from scan to diagnosis.
Forward-Looking Statements
This press release may contain forward-looking statements that
are subject to risks and uncertainties. All statements that are not
historical facts contained in this press release are
forward-looking statements. Such statements include, but are not
limited to, those relating to the Company’s expectations regarding
the consummation of the proposed offering and the intended use of
proceeds therefrom. In some cases, you can identify forward-looking
statements by terminology such as “can,” “might,” “believe,” “may,”
“estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,”
“should,” “could,” “expect,” “predict,” “potential,” or the
negative of these terms or other similar expressions.
Forward-looking statements are based on information the Company has
when those statements are made or management’s good faith belief as
of that time with respect to future events and are subject to risks
and uncertainties that could cause actual performance or results to
differ materially from those expressed in or suggested by the
forward-looking statements. Factors that could cause actual results
to differ materially from those currently anticipated include:
risks related to (i) Nanox’s ability to continue to develop of the
Nanox imaging system; (ii) Nanox’s ability to successfully
demonstrate the feasibility of its technology for commercial
applications; (iii) Nanox’s expectations regarding the necessity
of, timing of filing for, and receipt and maintenance of,
regulatory clearances or approvals regarding its technology, the
Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and
its ongoing compliance with applicable quality standards and
regulatory requirements; (iv) Nanox’s ability to realize the
anticipated benefits of acquisitions, which may be affected by,
among other things, competition, brand recognition, the ability of
the acquired companies to grow and manage growth profitably and
retain their key employees; (v) Nanox’s ability to enter into and
maintain commercially reasonable arrangements with third-party
manufacturers and suppliers to manufacture the Nanox.ARC; (vi) the
market acceptance of the Nanox imaging system and the proposed
pay-per-scan business model; (vii) Nanox’s expectations regarding
collaborations with third-parties and their potential benefits; and
(viii) Nanox’s ability to conduct business globally; (ix) changes
in global, political, economic, business, competitive, market and
regulatory forces; (x) the costs incurred with respect to and the
outcome of the securities class action litigation and the SEC
inquiry we are currently subject to and any similar or other claims
and litigation we may be subject to in the future; and (xi) risks
related to business interruptions resulting from the COVID-19
pandemic or similar public health crises, among other things.
For a discussion of other risks and uncertainties, and other
important factors, see the section titled “Risk Factors” in Nanox’s
Annual Report on Form 20-F for the year ended December 31, 2022,
and subsequent filings with the U.S. Securities and Exchange
Commission. The reader should not place undue reliance on any
forward-looking statements included in this press release.
Except as required by law, Nanox undertakes no obligation to
update publicly any forward-looking statements after the date of
this press release to conform these statements to actual results or
to changes in the Company’s expectations.
CONTACTS:
Media Contact:
Rachael RoselliICR WestwickeNanoxPR@icrinc.com
Investor Contact:
Mike CavanaughICR Westwickemike.cavanaugh@westwicke.com
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From Apr 2024 to May 2024
Nano X Imaging (NASDAQ:NNOX)
Historical Stock Chart
From May 2023 to May 2024